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Abstract: The diagnosis of rabies is routinely based on
clinical and epidemiological information, especially when
exposures are reported in rabies-endemic countries.
Diagnostic tests using conventional assays that appear to
be negative, even when undertaken late in the disease and
despite the clinical diagnosis, have a tendency, at times, to
be unreliable. These tests are rarely optimal and entirely
dependent on the nature and quality of the sample
supplied. In the course of the past three decades, the
application of molecular biology has aided in the
development of tests that result in a more rapid detection
of rabies virus. These tests enable viral strain identification
from clinical specimens. Currently, there are a number of
molecular tests that can be used to complement conven-
tional tests in rabies diagnosis. Indeed the challenges in the
21st century for the development of rabies diagnostics are
not of a technical nature; these tests are available now. The
challenges in the 21st century for diagnostic test develop-
ers are two-fold: firstly, to achieve internationally accepted
validation of a test that will then lead to its acceptance by
organisations globally. Secondly, the areas of the world
where such tests are needed are mainly in developing
regions where financial and logistical barriers prevent their
implementation. Although developing countries with a
poor healthcare infrastructure recognise that molecular-
based diagnostic assays will be unaffordable for routine
use, the cost/benefit ratio should still be measured.
Adoption of rapid and affordable rabies diagnostic tests
for use in developing countries highlights the importance
of sharing and transferring technology through laboratory
twinning between the developed and the developing
countries. Importantly for developing countries, the benefit
of molecular methods as tools is the capability for a
differential diagnosis of human diseases that present with
similar clinical symptoms. Antemortem testing for human
rabies is now possible using molecular techniques. These
barriers are not insurmountable and it is our expectation
that if such tests are accepted and implemented where
they are most needed, they will provide substantial
improvements for rabies diagnosis and surveillance. The
advent of molecular biology and new technological
initiatives that combine advances in biology with other
disciplines will support the development of techniques
capable of high throughput testing with a low turnaround
time for rabies diagnosis.
Validated diagnostic tests that confirm the presence of rabies virus
or a lyssavirus variant have been the foundation of rabies control
strategies in many countries. Historically, histopathological tech-
niques such as the Sellers Stain technique [1] were used to determine
the presence of Negri bodies as rabies virus-specific antigen, however
due to poor sensitivity and specificity this technique is no longer
recommended by the World Health organization (WHO). The
Fluorescent Antibody test (FAT) [2] relies on the ability of a detector
molecule (usually fluorescein isothiocyanate) coupled with a rabies
specific antibody forming a conjugate to bind to and allow the
visualisation of rabies antigen using fluorescent microscopy tech-
niques. Microscopic analysis of samples is the only direct method
that allows for the identification of rabies virus-specific antigen in a
short time and at a reduced cost, irrespective of geographical origin
and status of the host. It has to be regarded as the first step in
diagnostic procedures for all laboratories. Autolysed samples can,
however, reduce the sensitivity and specificity of the FAT. The
Rabies Tissue Culture Infection Test (RTCIT) [3] and the Mouse
Inoculation Test (MIT) [4] are based on the propagation and
isolation of the virus. These diagnostic tests are used to detect virus
particles either directly in tissue samples (FAT) or indirectly in
animals and in tissue culture (MIT and RTCIT, respectively). The
rationale for the use of virus isolation (RTCIT/MIT) from a sample
where there is a suspicion of infection with rabies virus is always
recommended, especially when Koch’s postulates are likely to be
met. Such amplification of the viral pathogen facilitates additional
molecular analysis to be undertaken, including sequencing of the
viral isolate and subsequent phylogenetic analysis. Conventional
diagnostic tests for rabies (FAT, RTCIT, MIT) are not labour
intensive and rely upon low throughput. The FAT can be completed
in less than two hours. In contrast, both the RTCIT and MIT
require longer turnaround times (4-days and 28-days, respectively).
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The fluorescent antibody virus neutralisation (FAVN) test [5]
and the Rapid Fluorescent Focus Inhibition Test (RFFIT) [6]
utilise a similar principle, to measure the level of virus neutralising
antibody in vaccinated individuals. ‘Indirect’ serological methods,
including the FAVN and RFFIT measure the host response to
infection/vaccination only and do not detect the presence of
infectious virus/antigen directly. However, host antibody detec-
tion (FAVN/RFFIT) is an indirect tool to measure the presence of
rabies virus in a non-immunised individual by evaluating the host
response to infection. The test may lack sensitivity and specificity,
and the interpretation of the test results may be difficult as the host
response to infection varies substantially between individuals. As
such, the negative predictive value of serological tests for rabies
diagnosis is considered poor. Therefore, serological assays are not
suitable as diagnostic tools for routine rabies testing.
These internationally approved methods have provided accurate
and timely information of animal and human rabies cases thereby
supporting surveillance for rabies and providing a greater under-
standing of the epidemiology of this disease (Box 1). For numerous
laboratories in rabies-endemic regions in the developing world, cost
and simplicity are critical factors in the delivery of disease diagnosis
and cannot be neglected, even when the principal consideration is for
rapid diagnosis. Therefore, cost and simplicity need to be considered
if new technologies are to be adopted in the regions of the world
where they are most needed.
Molecular tools based on the detection and manipulation of the
genetic information of the virus are becoming more widely
accepted and accessible for the diagnosis of rabies. The advent of
molecular biology is changing the face of diagnostic virology
generally enabling high throughput and short turnaround-time
analysis of samples. In the 21st century, it is expected that
diagnostic virology techniques for high throughput rabies virus
detection will progress rapidly towards the use of molecular
diagnostics replacing more conventional testing techniques such as
virus isolation and histopathology. It is also possible that
immunological tests, measuring ‘surrogate’ markers such as
cytokines and electrolytes, will augment the standard diagnostic
approach; nevertheless they will continue to remain oddities
outside the realms of the routine diagnostic laboratory and be
confined to a few reference laboratories. Semi-automated or
automated instruments and robotics-based techniques are useful
when large numbers of the same test are undertaken and these
tests will continue to increase in popularity and use, especially in
central reference laboratories rather than in each local or regional
facility. New technological advances will undoubtedly be faster,
more accurate and may, in time, offer a cost-effective alternative to
traditional rabies diagnostic tests. These paradigm shifts including
modern advances in technology will lead to the effective control of
rabies in animals and wildlife [7] (Box 2). This review provides
information on some of the latest developments and diagnostic
techniques for determining the presence of rabies virus or nucleic
acid in diagnostic samples.
The principal focus of this review is to highlight the new
developments in virology related to techniques for the diagnosis
and surveillance of rabies. Literature reviews were identified
through Web of Science, PubMed and Scopus using various
search phrases. This review also drew on information provided to
international organisations, mainly WHO and OIE, funded by the
UK Department for Environment, Food and Rural Affairs (Defra)
in an advisory context on diagnostic and surveillance strategies for
rabies. This review however, does not reflect the views of Defra,
WHO or OIE. This review provides information on some of the
latest developments and diagnostic techniques for determining the
presence of rabies virus in diagnostic samples. Our aim is to
provide a viewpoint on the current thinking in diagnostic virology
for rabies, reflecting the ‘neglected’ nature of this tropical disease
and the contrasting needs of diagnostic laboratories in developed
and developing countries.
Antigen detection–based assays
Development of Rapid Immunohistochemical Test (dRIT)
in the evaluation of suspect rabies tissue samples
A direct Rapid Immunohistochemical Test (dRIT) for the
postmortem detection of rabies virus antigen in brain smears has
been developed [8]. Using a cocktail of highly concentrated and
purified biotinylated monoclonal antibodies, rabies antigen can be
detected by direct staining of fresh brain impressions within 1 hour.
This test employs anti-rabies monoclonal antibodies specific for the
nucleoprotein, a viral protein produced in abundance during
productive infection. The FAT is based on antibodies specific for
the same protein but, being conjugated to fluorescein isothiocyanate,
requires a fluorescent microscope to visualise any specific antibody
bound to viral protein within the test sample [2]. In contrast, the new
Box 1. Key Learning Points
1. Validated diagnostic tests capable of confirming the
presence of rabies virus in clinical samples have
improved the quality, accuracy and speed of rabies
diagnosis in many national reference laboratories there-
by supporting rabies control strategies with the global
vision of dog rabies elimination in developing countries.
Ante-mortem testing for human rabies is now possible
using molecular techniques.
2. Adoption of rapid and affordable rabies diagnostic tests
for use in developing countries highlights the impor-
tance of participation in projects that link laboratories
from the developed and the developing countries.
3. The advent of molecular biology and new technological
initiatives that combine advances in biology with other
disciplines will support the development of microchip,
biosensor and robotics-based techniques capable of high
throughput testing with a low turnaround time for rabies
diagnosis.
Box 2. Key Manuscripts in the Field
1. Barrat J (1996) Simple technique for the collection and
shipment of brain specimens for rabies diagnosis. In:
Meslin FX, Kaplan MM, Koprowski H, editors. Laboratory
techniques in rabies. Geneva: World Health Organisation.
pp 425–432.
2. Bourhy H, Kissi B, Tordo N (1993) Molecular Diversity of
the Lyssavirus Genus. Virology 194: 70–81.
3. Rupprecht CE, Hanlon CA, Slate D (2006) Control and
prevention of rabies in animals: paradigm shifts. Devel-
opments in Biologicals 125: 103–111.
4. Sacramento D, Bourhy H, Tordo N (1991) PCR technique
as an alternative method for diagnosis and molecular
epidemiology of rabies virus. Molecular Cellular Probes 5:
229–240.
5. Willoughby RE Jr, Tieves KS, Hoffman GM, Ghanayem NS,
Amlie-Lefond CM, Schwabe MJ, Chusid MJ, Rupprecht CE
(2005). Survival after treatment of rabies with induction
of coma. N. Engl. J. Med. 16: 2508–1514.
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dRIT antibody cocktail is biotinylated such that following a short
incubation with a streptavidin-peroxidase complex, antibody-antigen
binding complexes can be visualised through the addition of the
substrate, 3-amino-9-ethylcarbazol. Performed on brain tissues, the
dRIT has proven as sensitive as the FAT for fresh specimens [9,10].
Brain impressions stained using the dRIT technique can be read
within one hour and the antibody cocktail used has been shown to
detect classical rabies virus strains (genotype 1) that have been
assessed [11]. Currently, the FAT is routinely used to detect virus
antigen in badly decomposed sample material. For the purpose of
testing samples in the developing world where suitable cold storage
for samples is often unavailable, this factor is important in the
development of new tests. This obstacle has been overcome through
evaluating sample preservation in phosphate buffered 50% glycerol at
a range of temperatures for different time periods prior to testing for
virus antigen. Glycerol saline solutions have been previously
recognised as suitable storage media for tissue samples in the absence
of cold storage [12] (Box 2). Using the dRIT in field studies in
Tanzania, viral antigen could be detected in samples after
considerable time periods post collection regardless of the regimen
of glycerol preservative used [11]. Applications of the dRIT to analyse
field samples in other rabies endemic regions have also proven highly
successful. Field trials in Chad sought to study the dRIT in direct
comparison to the FAT to attempt to confirm previous studies as to
the incidence of rabies within a district known to be endemic. In this
study, results between the two tests were 100% in agreement [9] and
the only issue regarding use of the dRIT over the FAT was the need
for the dRIT kit to be stored refrigerated prior to use. The dRIT will
enable developing countries to perform routine rabies surveillance at
greatly reduced cost and without the need for prohibitively expensive
microscopic equipment along with the expertise and financial input
needed to maintain them. The cost effectiveness of the dRIT will
allow knowledge and technology transfer to areas of the developing
world that currently are unable to diagnose rabies cases.
Immunochromatographic techniques
Another method for the detection of rabies virus antigen from
postmortem samples is a recently developed rapid immunodiag-
Table 1. Conventional, gel-based PCR-assays for the detection rabies virus.
PCR Primer name Direction Sequence Details Position Fragment length Author
heminested 20R R AGCTTGGCTGCATTCATGCC [65]
21F F ATGTAACACCCCTACAATG 55–73 210
23F F CAATATGAGTACAAGTACCCGGC 122
nested RabN1 F GCTCTAGAACACCTCTACAATGGATGCCGACAA 1st round 59–84 1477 [18]
RabN5 R GGATTGAC(AG)AAGATCTTGCTCAT 1514–1536
RabNF F TTGT(AG)GA(TC)CAATATGAGTACAA 2nd round 135–156 762
RabNR R CCGGCTCAAACATTCTTCTTA 876–896
heminested P510 F ATA GAG CAG ATTTTC GAG ACA GC 510-531 [66]
P942 R CCC ATA TAA CAT CCA ACA AAG TG 1st round 965-942 455
P784 R CCT CAA AGT TCT TGT GGAAGA 2nd round 805-784 295
standard N 1161 F AAG AAC TTC AAG AAT ACG AGG C 1161-1182 418 [67]
N 1579 R TTC AGC CAT CTC AAG ATC GG 1579–1560
standard 113 F GTAGGATGATATATGGG RT only [20]
509 F GAGAAAGAACTTCAAGA 377
304 R GAGTCACTCGAATATGTC
standard F ACT GAT GTA GAA GGGAAT TG N-gene 533 [68]
R GAA CGG AAG TGG ATG AAA TA
F TAA TCC CAG AGA TGC AAT G-gene 406
R CCT CAC AGT CTG GTC TCACC
nested Primer 1 F GAAGCCTGAGATTATCGTGG 1st round 63–82 304 [23]
Primer 2 R CCCTTCTACATCAGTACG 349–367
Primer 3 F TGAGTACAAGTACCCTGC 2nd round 90–107 139
Primer 4 R GGAACATACATCGTCAGG 229-211
standard N1 F TAGGGAGAAGGATCGTGGAGCACCATACTCTCA 611-632 179 [51]
N2 R GATGCAAGGTCGC ATATGAGTACCAG
CCCTGAACAGTCTTCA
790-769
standard N12 F GTAACACCTCTACAATGG 57-74 [52]
N40 R GCTTGATGATTGGAACTG 1368-1349
nested N1 F TTT GAG ACT GCT CCT TTT [22]
N4 R GCT TGA TGA TTG GAA CT
JW 4 F AGAATGTTTGAGCCACGGCA
JW 5 R TCAGGTGAAACCAGAAGTCC
doi:10.1371/journal.pntd.0000530.t001
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nostic test (RIDT) based on the principles of immunochromato-
graphy [13]. The immunochromatographic lateral flow strip test is a
one-step test that facilitates low-cost, rapid identification of various
analytes including viruses [14]. Briefly, suspect material is subjected
to a test device similar to a lateral flow device. Conjugated detector
antibodies attached to two different zones on a membrane indicate
the presence of viral antigen. Preliminary validation studies with a
limited number of samples showed that the RIDT might have great
potential as a useful method for rabies diagnosis without the need for
laboratory equipment [13]. However, thorough validation includ-
ing various circulating variants of RABV and other lyssaviruses is
still needed before this test could be relied upon and be used as an
alternative for the gold standard FAT.
Nucleic acid detection–based assays
Reverse-transcriptase polymerase chain reaction (RT-PCR)
Various conventional RT-PCR protocols for the diagnostic
amplification of lyssavirus genome fragments have been published
(Tables 1–3). Since primers were selected from conserved regions of
the genome, most assays amplify parts of the nucleoprotein (N-)
gene as earlier proposed [15]. In generic approaches intended to
detect all lyssaviruses either hemi-nested or fully nested amplifica-
tions are used and have applications for both antemortem (saliva,
CSF, brain) and postmortem samples (principally brain tissue)
(Table 2). Some of these diagnostic procedures are also applied for
further virus characterization, including sequencing reactions [16]
or restriction fragment length polymorphism (RFLP) [17]. Also,
strain-specific RT-PCRs have been developed to distinguish various
rabies virus (RABV) strains in a particular region [18].
Classical RT-PCR assays proved to be a sensitive and specific
tool for routine diagnostic purposes [19,15], particularly in
decomposed samples [20,21,22] or archival specimens [23,24].
The sole detection of amplified RT-PCR products by gel-based
systems however, especially when using hemi-nested RT-PCRs
generates the risk of cross-contamination, does not allow an exact
quantification of genome copies and does not include tests for
specificity [25]. Hybridisation methods [26] and PCR-ELISA
methods were established to overcome these difficulties [27],
although these techniques have not become universally accepted.
Additionally, many laboratories now use partial sequencing to
confirm the detection of a lyssavirus and obtain data that can be
used in a phylogenetic analysis of viruses circulating in a specific
region. The importance of sequencing the PCR products was
highlighted in an experimental study [28]. This study demon-
strated that although the nested RT-PCR was shown to be the
most sensitive of the diagnostic techniques employed, host
genomic amplicons of the same size as the target amplicons were
observed on the agarose gels, which were subsequently confirmed
as false positives following direct sequencing [28].
TaqMan RT-PCR
With the introduction of fluorogenic probes, detection of sequence
specific templates can be achieved in real-time. Specificity is ensured
by an inherent hybridization reaction, and cross-contamination is
avoided due to the closed tube nature of the test [29,30].
Consequently, for RABV and other lyssaviruses, various PCR assays
using TaqMan technology have been described (Tables 4–5). A
generic real-time TaqMan-PCR for the detection and differentiation
of lyssavirus genotypes 1, 5, and 6 has also been developed [31]. This
assay utilises a pan-lyssavirus primer set, which has been shown to
amplify a large panel of representative lyssaviruses, with probes
specifically designed to discriminate between classical rabies virus and
the European Bat Lyssaviruses type-1 and -2 (EBLV-1 and EBLV-2).
PCR assays using TaqMan technology have applications for
antemortem and postmortem samples. The pan-lyssavirus primer
Table 2. Conventional, gel-based PCR-assays for the generic detection of all lyssavirus species.
Genotype PCR Primer name Direction Sequence Details Position
Fragment
length Author
All standard N1 F TTT GAG ACT GCT CCT TTT 587-605 443 [26]
N2 R CC CAT ATA GCA TCC TAC 1029-1013
heminested JW12 F ATGTAACACCYCTACAATG universal lyssavirus primer 55–73 [69]
JW6 (DPL) R CAATTCGCACACATTTTGTG 1st round (DUVV, RABV, LBV) 660–641 605
JW6 (E) R CAGTTGGCACACATCTTGTG 1st round (EBLV-1 and 2)
JW6 (M) R CAGTTAGCGCACATCTTATG 1st round (MOKV)
JW10 (DLE2) R GTCATCAAAGTGTGRTGCTC 2nd round (DUVV, LBV, EBLV-2) 636–617 581
JW10 (ME1) R GTCATCAATGTGTGRTGTTC 2nd round (MOKV, EBLV1)
JW10 (P) R GTCATTAGAGTATGGTGTTC 2nd round (RABV)
nested D017 F AGATCAATATGAGTAYAART-
AYCC
2nd round forward primer
instead of JW12, otherwise
identical to Heaton et al.
139–163 497 [70]
nested LISEBL1F F AAGATGTGTGCCAACTGGAG 1st round [71]
LISEBL1R R ATGTTTGAGCCAGGGCAAGA
LISEBL2F F TACTGCTTATGAGGATTGTTC 2nd round
LISEBL2R R AAGAACTTCGAGGAAGAGATC
nested GRAB1F F AARATNGTRGARCAYCACAC 1st round 538-557 373 [72]
GRAB1R R GCRTTSGANGARTAAGGAGA 911-892
GRAB2F F AARATGTGYGCIAAYTGGAG 2nd round 574-593 259
GRAB2R R TCYTGHCCIGGCTCRAACAT 833-814
doi:10.1371/journal.pntd.0000530.t002
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set can also be used in conjunction with a specific dye such as SYBR
Green to allow for rapid detection of the amplicons. Validation of
probe based assays relies on the availability of representative viruses
or nucleic acid. However, for some lyssavirus genotypes only a limited
number of viruses or sequences are available for primer/probe
design, and they may not represent the genetic diversity of all current
variants that are circulating. Single mutations for the North American
RABV strains [32] in the region of the primers or the probe can alter
the sensitivity of the PCR. Thus the genetic diversity among
lyssaviruses may hamper the use of a single assay for all lyssaviruses.
As such scanning surveillance may benefit more from the use of a
pan-lyssavirus primer SYBR green assay rather than a strain or
specific based assay.
Nucleic acid sequence-based amplification (NASBA)
The use of a rapid automated NASBA technique was successfully
applied to the ante-mortem saliva and cerebrospinal fluid (CSF) of
four rabies patients in Thailand and shown to have a ten-fold
increase in sensitivity compared to RT-PCR [33]. The assay
detected rabies viral RNA as early as two days after onset of
symptoms. The NASBA technique involves the use of three
enzymes (reverse transcriptase, RNase H and T7 RNA polymerase)
to synthesise multiple copies of target RNA under isothermal
conditions. Briefly, a large number of RNA copies are generated
using a pair of specific primers, one of which contains the T7 RNA
polymerase binding site, and the other which has an electro-
chemiluminescence detection region attached to the 59 end. The
Table 3. Conventional, gel-based PCR-assays for the detection of lyssavirus species other than RABV.
Genotype PCR
Primer
name Direction Sequence Details Position
Fragment
length Author
EBLV-1 hemi-nested N1001fw CAGAGTTGTGCACCCCATGAA 1061-1081 475 [73]
1066fw GAGAGAAGATTCTTCAGGGA 1136–1155 400
304rv TTGACAAAGATCTTGCTCAT 1517-1536
nested N1161 F AAGAGCTACAGGATTACGAGG First round 1161-1181 373 [74]
N1534 R GACAAAGATCTTGCTCATGA 1534-1514
EBLV-1nF F TTGGCAGATGATGGGACAGT Second round 1211-1230 216
EBLV-1nR R TCCCTTATCTAATCAGGGGA 1427-1408
EBLV-2 nested EBLV-2F F TCATGGTCAATGGGGGAAAG First round 1226–1245 229 [74]
EBLV-2R R TTGGGATGGAGCAGGAAGAG 1455–1436
EBLV-2nF F CAAAAATCCCACATCAAAAG Second round 1249–1269 180
EBLV-2nR R TCTTAGTTTTTTTCTTTCCCC 1429–1409
LBV standard LagNF F GGGCAGATATGACGCGAGA [75]
LagNR R TTGACCGGGTTCAAACATC
LBV, WCBV,
MOKV
nested N1F F ATGGAKTCWGAMAASATTGT First round 71-90 595 [76]
N550B R GTRCTCCARTTAGCRCACAT 647-666
N70F F GAYCAATATGARTATAARTA Second round 140-159 439
N490B R TCCATYCTRTCTGCWACATT 560-579
WCBV nested F AATATCCTGCCATTACAGATTA First round 165-177 606 [76]
R TCATATGCAGTGACAACTGTGC 750-771
F ATGATGTGTGCTCCTATCTAGCA Second round 273-295 394
R GGTACTCCAATTGGCACACATC 646-667
ABLV hemi-nested NP1087 F GAGAAAGAG[A/C]T[G/T]CAAGA[A/C/T]TA N-gene [77]
NP1279 R CAG AGACATATCT[G/C]C[G/T][G/T]ATGTG
NP1227 R CTTCA [C/T]C[G/T]ACC[A/T][C/T][C/T]GTTCATCAT)
ARV nested F F AGTATCCTGCCATTGGGAATCA First round 86–107 616 [28]
R R GACTGTTGTAACTGCATATGAG 681–702
NF F ATGACGTCTGTTCTTATCTTGCT Second round 203–225 376
NR R ATGTGTGCAAATTGGAGCACG 577–597
KHUV nested F F AATACCCGGCTATTGTGGATAG First round 86–107 615 [28]
R R GAACTGTTGTGACCGCATATGA 680–701
NF F ATGATGTCTGTTCTTATTTGGCC Second round 203–225 375
NR R AATGTGTGCTAACTGGAGCACA 576–597
IRKV nested F F AATACCCTGCGATTGATGATAA First round 86–107 615 [28]
R R GAACAGTTGTGACTGCATATGA 680–701
NF F ATGATGTGTGCTCTTACTTGGCT Second round 203–225 375
NR R AATGTGTGCAAATTGGAGCACA 576–597
doi:10.1371/journal.pntd.0000530.t003
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amplified RNA is detected using an automated reader, enabling
rapid throughput testing. It is relatively easy to use and the whole
process from extraction to detection can take as little as four hours.
This technology has already been applied for point of care testing of
bacterial pathogens [34] and viral pathogens [35,36]. The NASBA
technique has also been adapted to investigate rabies virus
replication in situ, whereby the relatively lower isothermal
temperatures of NASBA compared to in-situ RT-PCR ensure that
cell integrity is maintained [37].
Loop-Mediated Isothermal Amplification (LAMP)
LAMP offers an alternative DNA amplification method to the
polymerase chain reaction for applications to the ante-mortem
saliva and CSF testing. The originators of the technique suggest
that it amplifies with high specificity, efficiency and without the
need for thermal cycling [38]. Amplification is achieved through
the specific binding of two inner and two outer primers to the
target sequence. The inner primers initiate strand synthesis whilst
the outer primers displace the inner primers, allowing them to self-
anneal to the nascent strand. This creates hairpin structures that
trigger further strand synthesis that in turn lead to concatenation
of the target sequence [38]. Polymerisation and strand displace-
ment are achieved using a single enzyme, Bst 1 DNA polymerase.
The technique is rapid, generating large quantities of target
sequence within minutes. For the amplification of RNA viruses, a
reverse transcription step is undertaken prior to the LAMP
reaction. Primer sets have been successfully developed to detect a
range of pathogenic viruses including West Nile virus [39],
Japanese Encephalitis virus [40], Foot and Mouth Disease virus
[41] and Chikungunya virus [42]. To assess the applicability of
LAMP to the detection of rabies virus we designed a primer set
using PrimerExplorer V4 software (Eiken Chemical Company
Ltd., Japan) that can detect the Challenge Virus Standard (CVS)
fixed strain of rabies virus (Table 6). In addition to the standard set
of four primers, two further loop-binding primers have been added
to increase the rate of strand displacement and synthesis [43]. The
reverse transcription and LAMP reactions were undertaken
simultaneously (RT-LAMP) in a single tube at 65uC using a
Table 4. Real-time PCR-assays for the detection of RABV.
PCR Primer/Probe name Role Sequence Position Author
TaqMan JW12 F ATGTAACACCYCTACAATG 55–73 [31]
N165–146 R GCAGGGTAYTTRTACTCATA 165–146
LysGT1 P ACAAGATTGTATTCAAAGTCAATAATCAG 81–109
TaqMan Probe P AAGCCCAGTATAACCTTAGGAAA 112 - 134 [65]
23F F CAATATGAGTACAAGTACCCGGC
20R R AGCTTGGCTGCATTCATGCC
SybrGreen(c) O1 F CTACAATGGATGCCGAC 66–82 [78]
R6 R CCTAGAGTTATACAGGGCT 201–183
TaqMan RB probe P TCAATTCTGATGACGAGGATTACTTCTCCGG [51]
1129F F CTGGCAGACGACGGAACC 1129
1218R R CATGATTCGAGTATAGACAGCC 1218
TaqMan gt1L F TACAATGGATGCCGACAAGA [79]
gt1P R CAAATC TTTGATGGCAGGGTA
AWgt1 P TCAGGTGGTCTCTTTGAAGCCTGAGA
TaqMan AZ-EF F GAATCCTGATAGCACGGAGGG 278–298 [32]
R CTTCCACATCGGTGCGTTTT 333–352
P CAAGATCACCCCAAATTCTCTTGTGGACA 303–331
AZ-SK F GTCGGCTGCTATATGGGTCAG 943–963
R ATCTCATGCGGAGCACAGG 995–1013
P TGAGGTCCTTGAATGCAACGGTAATAGCC 965–993
CASK F TCATGATGAATGGAGGTCGACTC 1226–1247
R TTGATGATTGGAACTGACTGAGACA 1296–1272
P AGAGATCGCATATACGGAGAT 1249–1270
NCSK F GGTGAAACCAGAAGTCCGGAA 1189–1209
R CCGTATATGCGATCTCTTTAGTCGA 1266–1242
P CTGTCTATACTCGAATCATGA 1211–1227
RAC F TGGTGAAACCAGGAGTCCAGA 1188–1208
R ATCTTTTGAGTCGGCCCCC 1255–1235
P CGGTCTATACTCGGATCAT 1211–1227
SCSK F ATGATGAAGACTATTTCTCCGGTGAG 1169–1191
R GTCGGCCTCCATTCATCATG 1246–1226
P CGGAGGCAGTCTATAC 1202–1219
doi:10.1371/journal.pntd.0000530.t004
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thermostable reverse transcriptase, hence avoiding the step process
inherent in an RT-PCR. Target amplification was monitored by
the incorporation of the double stranded DNA binding fluor-
ophore picogreen (Figure 1a) or by separation on a 1% agarose gel
(Figure 1b). At a constant temperature of 65uC, CVS RNA could
be detected within 30 minutes.
Development of RT-LAMP assays for use in diagnosis and
surveillance is challenged by the considerable sequence variation
observed within the rabies virus genome [44] that can frustrate
specific primer design. Preliminary attempts at this suggest that
multiple combinations of primers (up to 12 different primers) can
lead to sensitive, rapid amplification of RABV genomes from a
wide range of geographical locations. The use of isothermal
amplification has the benefit of reducing the technological
requirements of thermal cycling used in RT-PCR. This in turn
offers the opportunity, when linked with lateral flow devices, to
develop surveillance protocols where testing can take place in the
field or in less sophisticated laboratories.
Microarray detection of lyssaviruses
Microarray linked to sequence independent PCR amplification
offers the ability to rapidly identify pathogenic viruses from post-
mortem samples [45,46,47]. We have undertaken a study that has
demonstrated the ability of a microarray to detect each of the
seven lyssavirus genotypes (VLA Weybridge, unpublished data).
The microarray is composed of oligonucleotide probes 70
nucleotides in length and includes probe sets for each of the seven
classified genotypes and sets for the unclassified lyssaviruses. The
Table 5. Real-time PCR-assays for the detection of lyssavirus species other than RABV.
Genotype PCR Primer/Probe name Role Sequence Position Author
EBLV-2 TaqMan JW12 F ATGTAACACCYCTACAATG 55–73 [31]
N165–146 R GCAGGGTAYTTRTACTCATA 165–146
LysGT6 P ACARAATTGTCTTCAARGTCCATAATCAG 81–109
EBLV-1 TaqMan JW12 F ATGTAACACCYCTACAATG 55–73 [79]
N165–146 R GCAGGGTAYTTRTACTCATA 165–146
LysGT5 P AACARGGTTGTTTTYAAGGTCCATAA 80–105
gt5L F GATCCCGATTTGAAAACAGC
gt5P R AGACCATGGCTCCAGCTAAA
AWgt5 P GGGATGAATGCTGCTAAATTAGACCCA
ABLV TaqMan LYSF-YB F GAACGCCGCGAAGTTGG 191–207 [70]
LYSR-YB R AGATCCCCTCAAATAACTCCATAGC 240–264
LYSF-YB-FAM P CGGACGATGTTTGCTCCTACCTAGCTGC 211–238
LYSF-FF F TCGGGAATGAATGCTGCAA 183–201
LYSR-FF R GGCAGAYCCCCTCAAATAACTC 267–247
LYSF-FF-FAM P ACCCCGATGATGTATGTTCTTACTTAGCTGCAG 208–239
ARV TaqMan F CTTCGTCAAGGTGGTTGAACATC 531–553 [28]
R TGGAGCACGATACCAAATTTCA 589–610
P CATTGATGACCACTCACAAGATGTGTGCAA 557–586
KHUV TaqMan F AACTGGGCATTGACCGGAG 355–373 [28]
R ACATGCATCCTTAGTGGGGCT 408–428
P CTAGACCTGACAAGAGATCCGACTGTAGCCG 376–406
IRKV TaqMan F GTAATTGGGCTCAGGCAGGAG 353–373 [28]
R AGGAGCCCGACTAAAGACGC 412–431
P ACAAGACCTTACTAGAGATCCAACAACACCGGAAC 375–409
doi:10.1371/journal.pntd.0000530.t005
Table 6. Details of oligonucleotide primers designed to specifically amplify the Challenge Virus Standard strain of RABV.
Primer Function Sequence (59- 39) TmuC Final Concentration
CVSF3 Forward outer primer AGCCCCCGACTTGAACAAAG 67.3 5 picomoles
CVSB3 Backward outer primer CTGTCAGAGCCCAATTCCCG 69.0 5 picomoles
CVSFIP Forward inner primer GCATTGCTGCTGCCAAGTAGGATTTTCAGGCATGAATGCCGCCAA 89.1 50 picomoles
CVSBIP Backward inner primer CATGTCCGGAAGACTGGACCAGTTTTATCTCCACTAGAGAGTTTGG 81.4 50 picomoles
CVSFLOOP Forward loop-binding primer GCATACATCCGGATCAAGT 64.7 25 picomoles
CVSBLOOP Backward loop-binding primer CTATGGAATCCTGATTGCACG 64.2 25 picomoles
doi:10.1371/journal.pntd.0000530.t006
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diagnostic capability of the array was illustrated showing the ability
of the array to detect RABV in a human case of rabies as the
amplified RNA bound specifically to the classical rabies virus
(genotype 1) probe set (Figure 2).
Antibody detection–based assays
Development of a novel ultrasensitive and stable
potentiometric immunosensor
A stable potentiometric immunosensor for the detection of various
analytes of interest from complex real world samples such as blood,
serum and milk has been described [48]. The biosensor detects enzyme
labelled immunocomplexes formed at the surface of polypyrrole
coated, screen-printed gold or silver electrodes. Detection is through a
secondary reaction that produces charged products with a shift in
potential, being measured by local changes in redox state, pH and/or
ionic strength. The magnitude of the change in potential is directly
related to the level of target in the matrix such that the assays are
quantitative and the numerical output is rapidly transmissible. The
bioassays produce very rapid results (5–15 minutes), are highly
reproducible (%CV,5%) and are ultra-sensitive (,50 fM). Thus this
sort of biosensor offers the rapidity of production of signal of a lateral
flow device with the sensitivity of third generation ELISAs.
Immunoassays can be developed in a sandwich or competitive format
for small (e.g. Digoxin; MW 780 Da) or large (e.g. hepatitis B surface
antigen;.300 kDa) molecules [49]. In addition to immunoassays, it is
also possible to detect specific nucleic acids and whole cells using the
technology. Due to the method of production of the electrode strips,
the base assays are inexpensive (,US$1 per strip) as is the detection
hardware (US$2,000). In addition, most immunoassays can be readily
adapted to this format with minimal additional optimisation.
Potentiometric immunosensors for detecting the rabies virus nucleo-
protein are in progress and offer the ability to rapidly screen complex
non-clarified matrices, possibly at pen-side, in a cost-effective manner.
Development of lentiviral pseudotypes for the
measurement or rabies virus neutralising antibodies
Serological assays are not suitable as diagnostic tools for routine
rabies testing as the host response to infection varies substantially
between individuals. However, serology is still useful, particularly
to monitor the development of the immune response. We would
suggest that detection of rabies antibodies in serum and CSF, early
after presentation and in the absence of a history of vaccination
may be a positive indicator for a therapeutic intervention. Viral
pseudotypes, the core of one virus coated with envelope protein
derived from a second virus, offers a safe alternative to the use of
pathogenic viruses in neutralisation assays. Using pseudotypes
expressing genotype 1 CVS-11 glycoprotein, high titre stocks
(1.3–3.26105 infectious units/ml) were produced that proved
100% specific and highly sensitive compared with neutralisation
titres achieved using the FAVN [50]. A high correlation was also
observed (r = 0.89). Using pseudotypes expressing EBLV-1 (geno-
type 5) and EBLV-2 (genotype 6) G-proteins, neutralising antibody
titres broadly correlated with the degree of G-protein diversity. A
vaccine study in Tanzania compared the two assays with
pseudotypes showing 100% specificity and 94.4% sensitivity to
the FAVN with a high correlation of antibody titres (r = 0.92).
Incorporation of Lagos bat virus (genotype 2), Mokola virus
(genotype 3) and Duvenhage virus (genotype 4) G-proteins, as well
as lacZ as a reporter gene, makes the pseudotype assay an
attractive option for serosurveillance in Africa and other resource
limited countries. In addition, as the pseudotype assay uses
substantially less input serum (10 ml) compared to FAVN and
RFFIT, multiple tests can be undertaken on samples where
collection volumes are limited or valuable e.g. bat sera.
Due to the neurotropic nature of rabies virus, infection results in
enormous viral replication in the CNS in the final stage of the
disease that leads to massive antigen and viral genome
concentrations. This makes detection of viral antigen in brain
tissue by tests such as the FAT or the dRIT [7] very robust and
relatively simple to perform, and these have become rapid gold
standard tests. As for detection of viral genome, approaches are
now available which process multiple specimens from nucleic acid
extraction through to genetic typing, with significantly reduced
risks of contamination. In addition, the use of TaqMan RT-PCR
or similar technologies on robotics platforms, allow for rapid large-
scale rabies detection, typing and quantification in real time
[32,31,51]. The development of PCR-based methods (Box 2)
provided an alternative method for post mortem rabies diagnosis
[26], and the possibility of ante mortem diagnosis of human rabies
[52]. RT-PCR methods invariably involve multiple transfers of
nucleic acids between different tubes. Coupled with the high
sensitivity of PCR methodologies, any small amount of contam-
Figure 1. Amplification of rabies virus RNA by reverse
transcription loop-mediated isothermal amplification (RT-
LAMP). For each reaction 1 mg RNA, prepared using TriZol (Invitrogen)
from normal mouse brain (1A, circles; 1B 2) or infected mouse brain
(1A, triangles; 1B, +) was added to a reaction mixture containing all six
primers at concentrations indicated in Table 1, Thermopol buffer (New
England Biolabs, USA), 0.2 mM dNTPs (Promega, UK), 2 mM MgSO4,
1 M betaine (Sigma, UK), 16 units Bst 1 polymerase (New England
Biolabs), 0.12 units Thermoscript reverse transcriptase, 50 nM ROX dye
(Invitrogen) and 1/1000 dilution of the intercolating dye picogreen
(Molecular Probes) in a final volume of 25 ml. The reaction was
incubated at 65uC for 1 hour in an MX3000P thermal cycler with data
collection at 80 second intervals. Samples were analysed in real time
(Figure 1A) or by separation in a 1% agarose gel (Figure 1B), the arrow
indicates a marker band with a size of 1.35 kilobase pairs.
doi:10.1371/journal.pntd.0000530.g001
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ination will undoubtedly produce false-positive results. Attempts
have been made to adapt RT-PCR to reduce manipulations
thereby reducing contamination risks. The visualisation of PCR
products by gel electrophoresis exposes facilities and operators to
large quantities of amplified material and thus many adaptations
have been directed at replacing this step. New and improved rapid
diagnostic tools for rabies using Taqman technology have been
developed that avoid cross-contamination due to the closed tube
nature of the test [29,30]. A further benefit of RT-PCR has been
to enable practical molecular characterization of rabies viruses
[26] that has added significantly to the understanding of virus
evolution and epidemiology. This approach has superseded the
use of monoclonal antibodies for typing and characterising new
strains of rabies virus. This has provided the evidence to support
the delineation of lyssaviruses into genotypes [53] (Box 2) and was
used for the classification of another four putative members of the
genus [54,55]. Also, this technique was a prerequisite for the
understanding of the molecular biology of lyssaviruses [56] and
underpinned future developments in rabies diagnosis and
prevention. It is likely that in the future microarray techniques
in combination with sophisticated bioinformatics and arrays with a
hierarchical set of probes will provide an alternative to rapid virus
discovery and characterisation.
The development of ‘real-time’ RT-PCR techniques allows the
quantification of this RNA in ‘real-time,’ giving a relatively quick
and reliable method for the measuring levels of viral RNA. PCR
based techniques are not currently recommended by the WHO for
routine post-mortem diagnosis of rabies. However, in laboratories
with strict quality control procedures in place and demonstrable
experience and expertise, these molecular techniques have been
successfully applied for confirmatory diagnosis and epidemiolog-
ical surveys. For these reasons, it is likely that international bodies
will accept their use in the future for routine rabies diagnosis.
Reverse transcription PCR has been reported to confirm rabies
diagnosis intra-vitam in suspect human cases, when conventional
diagnostic methods have failed and post-mortem material is not
available (Box 1) [57]. Rabies virus RNA can be detected in a
range of biological fluids and samples (e.g. saliva, CSF, tears, skin
biopsy sample and urine). Owing to the intermittent shedding of
virus, serial samples of fluids such as saliva and urine should be
tested but negative results should not be used to exclude a
diagnosis of rabies. All positive PCR results should be sequenced
to confirm the origin of the virus and rule out possible
contamination. In terms of the RNA concentrations in the brain,
the sensitivity especially of nested or real-time PCRs may be
beyond the threshold needed for routine post-mortem testing.
Also, contamination of negative samples could lead to an
unjustifiable administration of a high number of costly post
exposure prophylaxis and would produce false data for the rabies
surveillance. However, with the introduction of accreditation for
laboratories, quality control measures are being implemented in a
growing number of laboratories worldwide. Such quality controls
for diagnostic rabies PCRs should encompass several measures,
including the inclusion of appropriate positive, negative, and
inhibition controls in assay runs. The consistency and the inter-
assay reproducibility should also be ensured over time by
monitoring performance. Only if laboratories meet the required
standard [58], can PCR fulfil its full potential. The use of PCR
should not be restricted only as a confirmatory diagnostic test for
decomposed samples but also as a powerful tool for virus typing
Figure 2. Microarray identification of rabies virus RNA prepared from a brain sample from a confirmed case of human rabies. Total
RNA was extracted using TriZol (Invitrogen) and treated with DNase I prior to conversion to double stranded DNA [45]. Non-specific amplification was
achieved using a DNA polymerase (Klen Taq, Sigma) and the products were labelled through binding of Alexa Fluor 555 reactive dye (Invitrogen) to
amplicons. Labelled target DNA was denatured at 95uC and chilled on ice before dilution in hybridization buffer and addition to the microarray slide.
Hybridization occurred at 50uC overnight. Slides were washed and the target-probe binding was captured using GenePix Pro 6.1 software (Molecular
Devices). Statistical analysis of the data was conducted using DetectiV software [64].
doi:10.1371/journal.pntd.0000530.g002
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and molecular epidemiology studies. The lack of standardization is
a major obstacle to the general use of PCR for rabies diagnosis,
especially in developing countries.
It is evident that the RT-PCR dominates genetic detection of
rabies virus and it seems probable that this technique will
dominate rabies diagnosis in the 21st century. However, we
should not discount alternatives that have the benefit of isothermal
amplification that will enable implementation in laboratories
where access to thermal cyclers is an obstacle. A NASBA
technique was successfully applied to the saliva and CSF of four
living patients with rabies and detected rabies viral RNA 2-days
after the onset of symptoms. This technique has also been adapted
to investigate rabies virus replication in-situ. LAMP also falls into
this category and can be adapted for use with lateral flow devices
thus making its application very simple.
Existing assays for rabies virus antibody prevalence studies
either require high containment facilities or do not distinguish
between neutralising and non-neutralising antibodies [59–60].
Recently however, a neutralisation assay using retroviral pseudo-
types was described [50], not bound by the restrictions listed above
and also allowing a choice of endpoint reporter proteins (b-
galactosidase, green fluorescent protein or luciferase) [61]. A
further benefit of this technique is its adaption to using small
volumes of sera thus making them useful for surveillance.
Currently, high-throughput rabies virus molecular detection
methods augment standard diagnostic tests or are in the process of
development and refinement for use alone. As we progress through
the 21st century, it is possible that these techniques will replace
conventional tests (Box 1). Obstacles to adoption include cost,
complexity and local acceptance of their use. It is also possible that
immunological tests by measuring ‘indirect’ markers such as
cytokines and electrolytes will increase in use. These tests however,
will probably remain in the realm of large reference laboratories
where resources allow the development of novel assays. As far as
semi-automated or automated instruments and robotics-based
techniques are concerned, they are useful when large numbers of
the same test are undertaken such as surveillance and companion
animal testing and these tests will continue to increase in
popularity and use, especially in central reference facilities. There
is a clear need to simplify molecular diagnostic techniques so these
tests can be applied universally in developing and developed
countries. It is likely that new developments will focus on
generating low volume and yet affordable diagnostic tests for
rabies. More use will be made of point-of-care (POC) diagnostic
testing using portable extraction techniques linked to PCR
machines with the use of lyophilised reagents to overcome cold-
chain dependencies in tropical countries. In the 21st century, these
technologies will have a demonstrable impact on people living in
developing countries, especially where rabies is still considered a
‘neglected’ disease. By contrast in the developed world, these new
technological advances will undoubtedly be faster, more accurate
and cost-effective leading to a ‘Theragnostics Approach’ that
combines therapeutics with diagnostics for the human treatment of
rabies. Interest in treating human rabies aggressively is gaining
momentum, largely due to the reported success in treating a 15-
year-old girl, in whom clinical rabies developed one month after
she was bitten by a bat, using a combination of therapeutic coma
with antiviral drugs whilst allowing for the host immune system to
confer immunity – The ‘Milwaukee Protocol’ (Box 2) [62,63].
Bioinformatics, genomics, proteomics, and functional genomics
are the molecular biology tools that are essential for the progress of
molecular ‘theragnostics’, where both early diagnosis and
monitoring of serology are critical factors for the successful
treatment of a rabies patient. In addition, theragnostics could
eliminate the unnecessary treatment of patients for whom rabies
immunotherapy is not appropriate i.e. immunosuppressed pa-
tients, resulting in substantial drug cost savings for the healthcare
system.
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